Business Context and Reporting Period
Company: Minerva Neurosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2016
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow).
- Gross Proceeds: Approximately $1 million.
- Shares Issued: 181,488 shares of common stock.
- Price Per Share: $5.51.
- Investor: David Kupfer (accredited investor).
Material Changes
The Company entered into a Common Stock Purchase Agreement on March 17, 2016, resulting in the issuance of new equity. This transaction represents a change in the Company's capital structure and cash position due to the private placement.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: The net proceeds from the private placement are designated for the advancement of pre-clinical and clinical programs, research and development, and general corporate purposes.
Regulatory Status: The sale was conducted in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The shares are not registered and may not be resold absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the full text of the Common Stock Purchase Agreement filed as Exhibit 10.1 for specific terms and conditions.
- Confirm the impact of the 181,488 new shares on total outstanding share count and potential dilution.
- Review subsequent periodic reports (10-Q/10-K) to track the utilization of the $1 million in proceeds against R&D milestones.
- Note that this filing does not contain audited financial statements or comprehensive liquidity data beyond the transaction proceeds.